51 results about "Clindamycinum" patented technology

The invention relates to compound gel containing clindamycin. The compound gels comprise effective dose of the clindamycin or medicinal salt or ester, Tretinoin and gel matrix. The invention is characterized in that the gel matrix is celluloses derivative, a preparation method as well as the detection and analysis methods of the gel are also related. The gel of the invention has the advantages of easy quality control, simple preparation technique and being suitable for industrial production.

The invention provides a polypeptide having the molecular weight of 3321.6 Da and having an amino acid sequence as shown in SEQ ID NO.1. The invention also provides six derivatives of the polypeptide. The polypeptide and the derivatives thereof provided by the invention have efficient broad-spectrum bacteriostatic effect on gram positive bacteria and gram negative bacteria (especially having good killing effect on anti-clindamycin anaerobic propionibacterium acnes), fungi and yeasts, and have high activity (the concentration for killing the propionibacterium acnes in vitro can be only 0.125 mg/L). The polypeptide and the derivatives thereof can be applied in preparation of microbial bacterial and fungal infection-controlling and anti-inflammatory products, wherein the products include externally-applied disinfectants, anti-bacterial agents, wound-protection or infection-prevention dressings, acne treating drugs, skin care products, cosmetics and the like. The polypeptide is designed and synthesized based on a tryptophan bromide-containing fragment of a marine biological sea urchin, has stronger bacteria inhibiting or killing and anti-inflammatory effects and better stability, and can be used as an antibiotic substitute.

The invention discloses a method for preparing clindamycin hydrochloride. The method comprises the following steps of: a) adding purified water into a chloroformic solution of clindamycin hydrochloride alcohol complex and washing; b) adding purified water into the washed organic phase, dripping hydrochloric acid to adjust PH value to be 2 to 3, standing and layering; c) adding activated carbon into a water phase obtained through separation and decoloring, and filtering; d) adsorbing filtrate by using a resin, and washing by using deionized water; e) desorbing by using methanol of which the mass concentration is more than 95 percent; f) concentrating a desorption solution under reduced pressure; g) adding acetone into concentrated dried materials, and stirring at the temperature of between 55 and 58 DEG C until the solution is clarified; h) dripping hydrochloric acid to adjust PH value to be 2 to 2.5; and i) reducing temperature to 0 to 5 DEG C, performing suction filtration under negative pressure to obtain web powder, washing by using iced acetone, and after suction filtration, drying to obtain the clindamycin hydrochloride. According to the method, the step of alcohol complex crystallization in the conventional process is eliminated; the process is simplified; production cost is reduced; and the weight yield and the quality of the whole batch of clindamycin hydrochloride are improved simultaneously.

A taste masked pharmaceutical composition of clindamycin, or a pharmaceutically acceptable salt(s), hydrate(s), solvate(s) and physiologically functional derivative(s) and precursors thereof, which includes all polymorphic forms, whether crystalline or amorphous comprising polyhydric alcohol(s); and one or more other pharmaceutically acceptable excipient(s). A process for preparation of a taste masked pharmaceutical composition of clindamycin or a pharmaceutically acceptable salt(s) thereof the said process comprising the steps of a) dry mixing clindamycin, polyhydric alcohol and other pharmaceutically acceptable excipient(s) to get a dry mixture; b) granulating the dry mixture above with a granulating liquid prepared by mixing the suitable pharmaceutically acceptable excipient(s) with aqueous/non-aqueous fluid to obtain a wet mass; c) drying the wet mass to obtain the discrete particles; d) lubricating the discrete particles obtained with a suitable lubricating agent and/or flavour(s).

The present invention discloses a compound gel preparation-compound tretinoin gel preparation for curing acnes. It is made up by using carbomer, glycerine, propylene alcohol, Tween, triethanolamine, clindamycin phosphate, tretinoin, EDTA and distilled water as raw material through a certain preparation process. Said invention also provides the concrete steps of its preparation method.

The invention relates to a method for purifying clindamycin hydrochloride. The process comprises process steps as follows: clindamycin hydrochloride adduct reaction liquid is subjected to macroporous resin adsorption and methyl alcohol desorption; obtained desorbed solution is subjected to reduced pressure distillation and concentration, then is dissolved by butyl acetate solvent, and is subjected to alkaline hydrolysis, alkaline extraction and activated carbon decoloration, and clindamycin alkali decolored solution is obtained; a clindamycin hydrochloride product is obtained after acetone crystallization conversion. According to the method, the macroporous resin is utilized in the clindamycin hydrochloride adduct reaction liquid, so as to facilitate alkaline hydrolysis and alkaline extraction and separation processes, reduce an emulsification effect, improve the clindamycin hydrochloride synthesis yield by more than 6%, reduce a solvent loss, lower production costs, and increase economic benefits; the DMF recovery is facilitated, the cost for raw materials is saved, the influence of DMF on the environment is reduced, and the ecological environment is preserved.

The invention relates to the technical field of intelligent measurement and control of trichloromethyl carbonate residues, in particular to an intelligent detection method for trichloromethyl carbonate residues in clindamycin hydrochloride. The method is completed by adopting a gas chromatography-mass spectrometer convenient for automatically leveling a column head of a chromatographic column in a matching manner. The detection method comprises the following steps: 1) preparing a raw material solution of a test sample; 2) preparing a test sample preparation solution; 3) preparing a reference substance solution; and 4) respectively and independently putting the prepared test sample raw material solution, the test sample preparation solution and the reference substance solution into a gas chromatography-mass spectrometer for detection. According to the invention, through the arranged cutting and leveling structure, the chromatographic column head can be automatically cut and leveled when the chromatographic column head of the chromatographic mass spectrometer body is replaced, and compared with manual leveling, the leveling efficiency and the leveling quality are greatly improved.

The invention discloses a specific clindamycin hydrochloride superfine powdered lyophilized preparation and a preparation method thereof. The preparation method uses clindamycin hydrochloride and triphosgene as raw materials, and comprises the following steps: performing chlorination reaction in the system of trichloromethane, N,N-dimethylformamide and antioxidant; hydrolyzing and alcoholizing to obtain clindamycin hydrochloride ethylate; decoloring and dealcoholizing to obtain high-purity clindamycin hydrochloride; and performing air-jet superfine crushing, and lyophilizing to obtain the specific clindamycin hydrochloride superfine powdered lyophilized preparation. The specific clindamycin hydrochloride superfine powdered lyophilized preparation has the advantages of good clarity, high stability, high purity, few impurities, small particles, large specific surface area, good solubility, small toxic and side effect, allergy prevention and the like.

The present invention relates to stable fixed dose topical formulations comprising an antiacne agent and an antibiotic, which exhibit storage stability at a temperature of about 40° C. and relative humidity of about 75% for a period of at least 3 months. Particularly, the present invention relates to stable fixed dose topical formulations comprising therapeutically effective amounts of (a) adapalene-containing microspheres and (b) clindamycin, a process for their preparation thereof and their use for the treatment of acne.

The invention relates to a medicine and a preparation for treating allergic rhinitis and a preparation method of same. The medicine includes Western medicines and traditional Chinese medicines, wherein the Western medicines include, by weight, 38-42 parts of clindamycin and 27-33 parts of lidocaine, and the traditional Chinese medicines include, by weight, 50-100 parts of storax, 15-30 parts of borneol, 10-30 parts of artificial musk, and 50-80 parts of centipeda minima. Through combination of the Western medicines and traditional Chinese medicines, damaged nasal mucosa can be rapidly repairedand allergy symptoms are eliminated. The medicine is convenient to use, has reliable and significant curative effects, is good in safety, and is suitable for adults and childrens.

The invention provides a lipid complex of tazarotene and clindamycin phosphate. The lipid complex is prepared mainly by utilizing synthetic phospholipids and stearamide, is wrapped with tazarotene and is further mixed with the clindamycin to prepare cream and gel which are mainly used for treating acne vulgaris. The lipid complex is simple in preparation technique, and the stability of pharmaceuticals can be ensured in the preparation process; compared with the common cream and gel, the lipid complex has the advantages that the skin medicine retention volume is higher, the content of medicine in local skins can be increased, and the therapeutic index can be improved.

The invention discloses a clindamycin hydrochloride emulsifiable paste and a preparation method thereof. The clindamycin hydrochloride emulsifiable paste is composed of clindamycin hydrochloride used as an active component and a pharmaceutical adjuvant. The pharmaceutical adjuvant comprises an oil-phase matrix, a hygroscopic agent, an emulsifier, an antiseptic, essence a pH value conditioning agent and purified water and is characterized in that the oil-phase matrix is a mixture of cetanol, lightweight liquid paraffin and albolene, the hygroscopic agent is propylene glycol, the emulsifier is Span-60, and the antiseptic is a mixture of ethylparaben, potassium sorbate and 2,6-di-t-butyl p-cresol. According to the invention, clindamycin hydrochloride is dispersed in inertial albolene during preparation of the emulsifiable paste, albolene is used for clathration of the raw material clindamycin hydrochloride, so hydrolysis of the raw material is avoided; moreover, the pH value of the prepared emulsifiable paste maintains 3.0 to 4.5, which enables the hydrolysis process of clindamycin to be effectively inhibited.

The invention provides a clindamycin phosphate vaginal tablet and a preparation process thereof. The clindamycin phosphate vaginal tablet is prepared from the following raw materials in parts by weight: 125 parts of clindamycin phosphate, 140-160 parts of lactose, 90-95 parts of microcrystalline cellulose, 7-8 parts of carboxymethyl starch sodium, 1.5-2.0 parts of magnesium stearate and 10-20 parts of a 1.8-2.2 wt% hydroxypropyl methylcellulose aqueous solution. The clindamycin phosphate vaginal tablet prepared by the preparation method disclosed by the invention is good in swelling rate and relatively large in adhesive force, better exerts the drug effect of clindamycin, shortens the drug use time and improves the use compliance of a patient.

The invention discloses a medicine spray for treating rhinitis and belongs to the technical field of medicine preparation. The medicine spray is prepared from the following raw materials in parts by weight: 20 to 32 parts of cynanchagenin, 15 to 33 parts of Japanese spicebush bark, 11 to 19 parts of tormentic acid, 8 to 12 parts of cycloartanol, 1 to 5 parts of homoplantaginin, 2 to 8 parts of clindamycin, 3 to 9 parts of capillarisin, 2 to 8 parts of glycyrrhizin, 3 to 7 parts of polygalic acid, 1 to 5 parts of synergists, 1 to 5 parts of acetone chloroform, 3 to 7 parts of sodium benzoate, 80 to 100 parts of distilled water, 2 to 10 parts of chlorine gluconate, 1 to 3 parts of paracetamol, 1 to 3 parts of benproperine, 1 to 5 parts of herb eriocaulon buergerianum and 2 to 8 parts of plant essential oil. The medicine spray has the advantages that the curative effect is obvious; no toxic or side effect exists; both symptoms and root causes can be treated; the treatment method is more reasonable; the exact curative effect can be achieved on relieving the disease and pain of rhinitis.

The invention discloses a veterinary compound preparation for treating a disease of the respiratory system of livestock and a preparation method of the veterinary compound preparation. The veterinary compound preparation is prepared from a main medicament doxycycline hydrochloride respectively together with one of lincomycin hydrochloride and clindamycin hydrochloride. The preparation method of the veterinary compound preparation comprises the following steps: respectively weighing a prescription amount of the doxycycline hydrochloride and one of the lincomycin hydrochloride and the clindamycin hydrochloride, adding into a proper amount of a solvent for injection, stirring and dissolving; respectively adding the prescription amount of an antioxidant and a metal complexing agent, stirring and dissolving; and replenishing the solvent for injection to a full dose, regulating the pH value, filtering, potting, sterilizing, cooling, inspecting by use of a lamp, printing words and packaging to obtain the veterinary compound preparation. The veterinary compound preparation disclosed by the invention has the advantages that (1) the composition is reasonable, and the adopted raw materials are all high-efficiency medicaments for treating the disease of the respiratory system of the livestock; (2) the preparation method is advanced, and the preparation is stable and long in storage life; (3) the curative effect is better than that of a single-prescription preparation of each medicament contained in the preparation disclosed by the invention; (4) the veterinary compound preparation is safe in use, clear in curative effect and controllable in quality.